JUN 21, 2018 7:30 AM PDT

Keynote Presentation: Paving the Path Towards Precision Medicine in Inflammatory Bowel Diseases

Speaker
  • Senior Director of Translational Research, Crohn's & Colitis Foundation
    Biography
      Dr. Andrés Hurtado-Lorenzo is the Senior Director of Translational Research at the Crohn's and Colitis Foundation. He is responsible for planning and oversight the Foundation's translational research portfolio that consist of a number research initiatives in the fields of: Precision Medicine, Genetics, Microbiome, Environmental Triggers, and Entrepreneurial Investing, a venture philanthropy initiative focused on accelerating product development in IBD. These initiatives aim to identify opportunities to translate observations in the laboratory and clinic into interventions that reach and benefit patients; from therapeutics and diagnostics to medical devices and procedures.

      Dr. Hurtado-Lorenzo is a translational scientist leader with previous proven success directing multidisciplinary teams focused on drug discovery and development for neurological diseases and rare diseases in the biotech and pharmaceutical industry (Wyeth, Pfizer, Proteostasis Therapeutics) from discovery to early clinical development. These efforts have resulted in the identification of candidate drugs currently evaluated in clinical trials.

      He obtained his Ph.D. in Molecular Medicine from the University of Manchester in the UK, where he pioneered work in the field of viral gene therapy for neurodegenerative diseases. He completed his postdoctoral work at Harvard Medical School, Massachusetts General Hospital and Columbia University, where he conducted groundbreaking research focused on molecular mechanisms of autophagy and other protein degradation pathways and their role in health and disease. His research has been published in books high impact factor publications like Nature Cell Biology and Nature Communications.

    Abstract

    Crohn’s disease and ulcerative colitis also known as inflammatory bowel diseases or IBD, are characterized by chronic, recurrent inflammation of the gastrointestinal tract, which results from the interplay between genetic predisposition, altered immune response, intestinal microbial dysbiosis and environmental factors. The course of the disease is variable, with some patients having much more aggressive disease than others. Half of the patients will develop severe complications like strictures, fistulas and abscesses, which require surgery. In addition, some patients experience frequent relapses while others achieve prolonged remission without any additional therapy. Such variability in prognosis represents the difference between an excellent long-term outcome or progressive disability. Therefore, the main challenge in managing IBD is the early detection, ideally at diagnosis, of patients with potentially severe disease course and variability in treatment outcomes. Thus, if precision medicine is to be applied in IBD, it will require the stratification of patients with a high risk of relapse and complications, and better characterization of patients who may respond preferentially to specific therapies. In this presentation I will highlight current advances towards the integration of clinical and molecular phenotypes for early prediction of complicated disease course at diagnosis and response to biological therapy. I will also highlight the current efforts of the Crohn’s and Colitis Foundation to build the largest biorepository and research exchange platform called IBD Plexus, which aims to integrate longitudinal clinical data and patient reported outcomes from than 40,000 patients along with genetic and multi-omics profiles from 7,000 IBD patients, and how this platform will accelerate the path towards precision medicine in IBD.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    Loading Comments...
    Show Resources